Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 23;16(1):20.
doi: 10.1186/s13048-023-01107-3.

Management of Borderline ovarian tumors (BOT): results of a retrospective, single center study in Switzerland

B Kipp  1 , A Vidal  2 , D Lenick  2 , C Christmann-Schmid  2
Affiliations

Management of Borderline ovarian tumors (BOT): results of a retrospective, single center study in Switzerland

B Kipp et al. J Ovarian Res. .

Abstract

Background: Borderline tumors are malignant epithelial ovarian tumors with a very low incidence. Thus experience in diagnostics and treatment is still rare. The aim of this study was to present and analyze data of women with borderline ovarian tumor (BOT) regarding clinical features, histological characteristics, diagnostics and treatment management.

Methods: In this single center retrospective study women with BOT treated at the Departement of Gynecology and Obstetrics at the Kantonsspital Luzern between 2011 and 2018 were analyzed according to their clinical and histological reports.

Results: A total of 42 women were enrolled. The median age was 58.5 with a range from 26 to 85, of which 31 (73.8%) were postmenopausal. Regarding the histological subtypes, 23 women (54.8%) had serous and 15 (35.7%) had mucinous BOT. Seromucinous histology was found in 3 patients (7.1%) and endometrioid in 1 woman (2.4%), respectively. All women underwent surgery. In a total of 39 women (92.9%) a complete surgical staging for BOT was performed. In 29 women (69.0%) staging was performed by laparoscopy, 13 (31.0%) underwent laparotomy. The mean follow up was 52 months (range = 16.3-101.4 months). During this period two patients, initially diagnosed in FIGO stage 1, recurred after 21.7 and 44 months, respectively, the second woman died after 53 months because of the BOT.

Conclusion: In the present study women were treated according to the international therapy recommendations and the rate of recurrence was very low. The most common risk factors for relapse are known to be FIGO stage, incomplete staging and peritoneal implants but were not present in our group. Thus further studies are necessary to investigate additional recurrence risks.

PubMed Disclaimer

Conflict of interest statement

all authors report no conflicts of interest in this work.

References

    1. Abascal-Saiz A, Sotillo-Mallo L, de Santiago J, Zapardiel I. Management of borderline ovarian tumours: a comprehensive review of the literature. Ecancermedicalscience. 2014;8:403. - PMC - PubMed
    1. Koensgen D, Weiss M, Assmann K, Brucker SY, Wallwiener D, Stope MB, et al. Characterization and Management of Borderline Ovarian Tumors - results of a retrospective, single-center study of patients treated at the Department of Gynecology and Obstetrics of the university medicine Greifswald. Anticancer Res. 2018;38:1539–1545. - PubMed
    1. du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, et al. Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) study group. Eur J Cancer. 2013;49:1905–1914. doi: 10.1016/j.ejca.2013.01.035. - DOI - PubMed
    1. Araujo KG, Jales RM, Pereira PN, Yoshida A, de Angelo AL, Sarian LO, et al. Performance of the IOTA ADNEX model in preoperative discrimination of adnexal masses in a gynecological oncology center. Ultrasound Obstet Gynecol. 2017;49:778–783. doi: 10.1002/uog.15963. - DOI - PubMed
    1. Gershenson DM. Management of borderline ovarian tumours. Best Pract Res Clin Obstet Gynaecol. 2017;41:49–59. doi: 10.1016/j.bpobgyn.2016.09.012. - DOI - PubMed